“This quarter, Celldex (CLDX) continued to demonstrate our leadership in the field of mast cell biology, presenting exciting data across our pipeline programs,” said Anthony Marucci, co-founder, president and CEO of Celldex. “Barzolvolimab is the first in the field to demonstrate clinical benefit in a large, randomized, placebo-controlled study of cold urticaria and symptomatic dermographism, and we were also pleased to report additional endpoints from our Phase 2 CSU study and promising data from CDX-622, the first stem cell factor neutralizing bispecific antibody to be studied in humans, which we designed to also target TSLP.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex appoints Lawver as Chief Commercial Officer
- Celldex’s Promising Phase II Trial Results Justify Buy Rating
- Celldex’s Promising Phase 2 Trial Results and Strong Financial Position Support Buy Rating
- Celldex’s Barzolvolimab Shows Promising Phase 2 Results, Justifying Buy Rating
- Celldex announces additional data on barzolvolimab